What is the best treatment for premenstrual dysphoric disorder (PMDD)?

Best Treatment for Premenstrual Dysphoric Disorder (PMDD)

Selective serotonin reuptake inhibitors (SSRIs), particularly paroxetine and fluoxetine, are the first-line treatment for PMDD, with continuous dosing being more effective than luteal-phase-only administration. 1, 2, 3

First-Line Treatment: SSRIs

SSRIs demonstrate robust efficacy in reducing premenstrual symptoms, with a standardized mean difference of -0.57 for overall symptom reduction 3. Among SSRIs, continuous paroxetine shows the greatest effect across all symptom domains (emotional, physical, and behavioral) 1, 2.

Dosing Strategy

• Continuous administration is superior to luteal-phase-only dosing (SMD -0.69 vs -0.39, p=0.03 for subgroup difference) 3
• Continuous dosing provides more consistent symptom control and should be the preferred approach 1, 3
• Luteal-phase dosing can be considered for patients preferring intermittent treatment, though efficacy is reduced 3

Alternative SSRIs

• Fluoxetine, sertraline, escitalopram, and citalopram are all effective options 2, 3
• Choice should be guided by side effect profile and patient tolerance 3

Expected Adverse Effects

Patients should be counseled about common SSRI side effects with specific risk increases 3:

• Nausea (OR 3.30) - most common
• Sexual dysfunction/decreased libido (OR 2.32)
• Insomnia (OR 1.99)
• Asthenia/decreased energy (OR 3.28)
• Somnolence/decreased concentration (OR 3.26)
• Dry mouth (OR 2.70)

Second-Line Treatment: Combined Oral Contraceptives

When SSRIs fail or are not tolerated, drospirenone/ethinyl estradiol (DROS/EE) in a 24/4 regimen is the most effective combined oral contraceptive for PMDD 1. This formulation shows particularly strong outcomes for both physical and emotional symptoms 1.

• The 24/4 regimen (24 active pills, 4 placebo) provides more stable hormone levels than traditional 21/7 formulations 1
• Drospirenone's anti-mineralocorticoid activity may specifically address bloating and fluid retention symptoms 4
• Continuous combined oral contraceptives have limited evidence for PMDD specifically 5

Third-Line Treatment: GnRH Analogs with Hormone Addback

For treatment-resistant PMDD (failure of both SSRIs and oral contraceptives), GnRH analogs with stable hormone addback represent the definitive treatment 6.

Implementation Strategy

• GnRH analogs (leuprolide, goserelin) suppress ovarian function completely 6
• Hormone addback is mandatory to prevent bone loss and menopausal symptoms 6
• Stable, low-dose estrogen and progesterone addback maintains symptom relief while protecting bone density 6
• This approach is highly effective but requires specialized knowledge for implementation 6

When to Consider

• Failed adequate trials of at least 2 SSRIs 6
• Failed trial of DROS/EE 24/4 oral contraceptive 6
• Severe functional impairment despite first-line treatments 6
• Patient preference after discussion of risks/benefits 6

Emerging Treatment: Selective Progesterone Receptor Modulators

Ulipristal acetate (a selective progesterone receptor modulator) shows clinically significant reduction in PMDD mental symptoms with negligible side effects 7. This represents a promising new mechanism targeting the underlying progesterone sensitivity in PMDD 7. However, long-term safety data in reproductive-age women are still needed before widespread recommendation 7.

Alternative Treatments with Limited Evidence

Other Psychiatric Medications

• Venlafaxine and duloxetine (SNRIs) show benefit but less evidence than SSRIs 8
• Alprazolam and buspirone have some supporting data but are not first-line 8

Supplements

• Calcium supplementation (1500 mg/day) is the only supplement with consistent therapeutic benefit 8
• Vitamin D should be maintained above 32-50 ng/mL 9
• Other supplements (omega-3, SAMe, St. John's wort) lack robust evidence specific to PMDD 8

Non-Pharmacological Approaches

• Cognitive behavioral therapy shows promise but access to trained professionals is limited 5, 8
• Light therapy has preliminary positive results requiring further investigation 2

Critical Diagnostic Requirement

Prospective daily symptom rating for at least two menstrual cycles is mandatory for PMDD diagnosis 6. Retrospective recall is insufficient and leads to misdiagnosis 6. Symptoms must:

• Occur exclusively in the luteal phase (week before menses) 10
• Resolve within days of menstruation onset 10
• Cause significant functional impairment 10
• Not be better explained by another psychiatric condition 5

Treatment Algorithm Summary

1. Start with continuous SSRI (paroxetine or fluoxetine preferred) 1, 2, 3
2. If SSRI fails or not tolerated: Switch to DROS/EE 24/4 oral contraceptive 1
3. If both fail: Refer for GnRH analog with hormone addback 6
4. Throughout: Add calcium 1500 mg/day supplementation 8

Common Pitfalls to Avoid

• Do not use standard oral contraceptives as first-line; SSRIs have stronger evidence 5, 3
• Do not prescribe GnRH analogs without hormone addback due to bone loss risk 6
• Do not diagnose PMDD without prospective symptom tracking 6
• Do not assume treatment failure without adequate trial duration (at least 2-3 menstrual cycles) 3
• Do not overlook the high suicide risk in PMDD patients; assess safety regularly 6